Biotechnology

  • Most Topular Stories

  • Genentech drug picked for pioneering $100M Alzheimer's trial

    News
    john
    15 May 2012 | 12:59 pm
    The NIH has agreed to help bankroll a pioneering $100 million study of Genentech's experimental Alzheimer's therapy crenezumab. Investigators will test the drug in a region of Colombia where a particular genetic mutation is known to trigger the early onset of Alzheimer's, with an eye to determining if they can stop the memory-wasting ailment before it starts. The NIH has agreed to pay for $16 million of the study, with private donors putting up $15 million more and Genentech adding the rest--about $65 million--to bankroll the effort. The announcement is part of an ambitious effort…

  • Researchers cure Type 1 diabetes in mice

    News
    mhollmer
    10 May 2012 | 4:22 pm
    A dose of antibodies, a bone marrow transplant and treatment with pancreas growth factor helped cure late-stage Type 1 diabetes in mice, researchers have found. The effort, led by City of Hope National Medical Center endocrinologist Defu Zeng, is detailed in the journal Science Translational Medicine. Bloomberg also reports on the findings with a solid story rounding up some of the crucial fine points. As always, take these findings with a grain of salt. Results in mice and other animal trials can be enticingly encouraging, with researchers subsequently finding that they can't repeat the…

  • Mice with big brains provide insight into brain regeneration and developmental disorders

    ScienceDaily: Biotechnology News
    15 May 2012 | 8:41 am
    Scientists have discovered that mice that lack a gene called Snf2l have brains that are 35 percent larger than normal. The research could lead to new approaches to stimulate brain regeneration and may provide important insight into developmental disorders such as autism and Rett syndrome.

  • Scientist uses stem cells to rebuild bone

    News
    mhollmer
    14 May 2012 | 4:16 pm
    In the move to use induced pluripotent stem cells to both repair and replace damaged bone tissue in patients, recent research by scientist Darja Marolt has helped advance the field in a major way. The investigator with The New York Stem Cell Foundation laboratory has used human embryonic stem cells to successfully grow bone tissue grafts, according to the foundation. And they're not just a half-hearted first attempt: In mice, the foundation claims, Marolt and her team have proven in a recent study that the new bone growth is strong enough to support major bone tissue regeneration,…

  • Biotechnology, Key to Realizing Africa's Full Agricultural Potential, says Ghana Minister

    CropBiotech Update
    11 May 2012 | 4:00 am
    Agricultural biotechnology has received firm backing from Ghana's Minister for Environment, Science and Technology Hon. Ms. Sherry Ayittey. The Minister's sentiments came during the second Open Forum on Agricultural Biotechnology in Africa (OFAB) all chapters annual planning meeting in Accra, Ghana on May 1, 2012. Hon. Ayittey noted that while Afri...
 
  • add this feed to my.Alltop

    News

  • Genentech drug picked for pioneering $100M Alzheimer's trial

    john
    15 May 2012 | 12:59 pm
    The NIH has agreed to help bankroll a pioneering $100 million study of Genentech's experimental Alzheimer's therapy crenezumab. Investigators will test the drug in a region of Colombia where a particular genetic mutation is known to trigger the early onset of Alzheimer's, with an eye to determining if they can stop the memory-wasting ailment before it starts. The NIH has agreed to pay for $16 million of the study, with private donors putting up $15 million more and Genentech adding the rest--about $65 million--to bankroll the effort. The announcement is part of an ambitious effort…

  • Payers likely to throw up hurdles to Pfizer's new RA drug

    john
    15 May 2012 | 10:45 am
    You know that old adage: The one with the gold makes the rules? For the latest exhibit, look no further than Pfizer's ($PFE) anticipated rheumatoid arthritis treatment tofacitinib. After an FDA advisory panel voted in favor of the drug last week, Reimbursement Intelligence surveyed 30 big payers, asking how they'd manage access to the new treatment if it wins final approval. More than three-fourths of payers said they'd require patients to fail on at least one TNF inhibitor, such as Abbott Laboratories' ($ABT) Humira or Johnson & Johnson's ($JNJ) Remicade, before…

  • First wave of AstraZeneca's CNS R&D group gets the ax

    john
    15 May 2012 | 10:24 am
    AstraZeneca isn't wasting any time in pushing ahead with draconian cuts to its neuroscience work in its big R&D hub south of Stockholm. The first 50 scientists have already been shown the door, according to local news reports, part of the first wave of 400 job cuts as AstraZeneca ($AZN) slashes a total of 1,100 positions at the research complex. "The first 50 left two weeks ago. Some will leave during the summer and others early this autumn and the whole move should be completed in December," AstraZeneca spokesperson Ann-Leena Mikiver told news agency TT. AstraZeneca has…

  • Newron soars on positive PhIII results, $26M pact for Parkinson's drug

    john
    15 May 2012 | 9:51 am
    Despite being left at the M&A altar last fall after a key partnership deal collapsed, Newron says it has successfully completed two late-stage studies of its experimental Parkinson's drug. And the Italian biotech used the opportunity to announce that it has garnered a 20 million euro licensing deal with Zambon for the drug. At the same time, Newron's founding CEO is exiting after 13 years at the biotech. Newron didn't release details on the data from the two Phase III studies of safinamide. But investigators assert that the drug achieved positive numbers for maintaining motor…

  • Buzz: Big Pharma suitors line up for a look at Amylin's books

    john
    15 May 2012 | 8:41 am
    One of the cardinal rules involved in deal-making focuses on the need to get as many buyers to the negotiating table as possible. The next big rule: Make sure everyone knows who's interested in bidding. Amylin--while maintaining a strict no comment policy ever since initial reports appeared the Bristol-Myers Squibb ($BMY) had made an offer--has scored on both points with a Bloomberg report out this morning assessing the line of potential bidders queuing up to take a confidential look at the books. By the business news service's count, fed by an inside source, Pfizer ($PFE),…
 
  • add this feed to my.Alltop

    About.com Biotech / Biomedical

  • Addressing the Ethical, Legal, and Social Implication of Genomic Research

    16 May 2012 | 12:59 am
    As the era of personalized medicine emerges, important ethical and legal questions arise about how personal genetic testing information is managed and used. For example, how should genetic information be used, by whom, and who should have access to it? As a result, there is a lot of current research on the ethical, legal, and social implications (ELSI) of scientific and medical advances from genomic DNA research. Many nations have allocated resources toward addressing these areas, such as the National Institutes of Health (NIH) ELSI Program....Read Full Post

  • Ten-Year Study Demonstrates Safety of Retroviral Gene Therapy Using T-Cells

    7 May 2012 | 11:08 am
    Researchers at the University of Pennsylvania completed a 10-year long follow up gene therapy safety study of patients that received an engineered gene which enabled immune system T-cells to recognize the HIV virus. In three trials between 1998 and 2002, immune system T-cells from the blood of 43 HIV-positive patients were infected with an modified retrovirus carrying an engineered gene called CD3-zeta. As a result, the CD3-zeta gene, which combined parts of the natural CD3 and CD4 genes to enable it to recognize the HIV virus and turn on the T-cell's immune response, became part of the…

  • Whitehouse Releases Guidelines for the Bioeconomy

    28 Apr 2012 | 6:26 pm
    The White House just released a National Bioeconomy Blueprint which outlines initiatives and policies for Federal government agencies to advance and promote development of a broad range of biology-related industries from biofuels through environmental sciences. Of course, a large portion of the report the report focuses on the largest segment of the bioeconomy, biomedical research.  Two of the six outlined objectives target the major challenges with developing and launching new drugs, diagnostic tests, and medical devices....Read Full Post

  • Researchers Find Age-Related Gene Regulators

    28 Apr 2012 | 6:09 pm
    Researchers in the UK appear to have found a set of epigenetically regulated genes that influence aging. The study published in the on-line journal PLoS Genetics associated chemical modifications in DNA (i.e., epigenetic marks) with age and aging characteristics, such as lung function, bone mineral density, blood pressure, of 172 female identical twins between 32 and 80 years old. They found 490 genes with that had changes in epigenetic marks that correlated with the age, but just 4 that correlated with differences in age-related traits, specifically LDL cholesterol levels, lung function, and…

  • Roche Abandons Takeover of Illumina

    25 Apr 2012 | 9:58 pm
    Roche's $46.8 billion bid to take over Illumina fell through when Roche allowed it to expire last week after Illumina's shareholders rejected Roche's attempt to appoint its own directors to Illumina's board. Although Roche has been actively pursuing this deal since December last year and agreed to sweeten the offer from $44.50 per share in cash to $51.00 per in the end of March, Roche declined to pursue the company further after the latest rebuff....Read Full Post
  • add this feed to my.Alltop

    Biotech Blog

  • Health Questions? Talk To A Doctor With MD247 Telemedicine

    Science: Biotechnology
    16 May 2012 | 4:52 am
    In order to protect the health of MD247 telemedicine program members, the provider of supplemental medical services has retracted a press release regarding heart attack symptoms.(PRWeb May 16, 2012)Read the full story at http://www.prweb.com/release...

  • WFT Cloud Announces Cloud-based Disaster Recovery Solution for SAP…

    Science: Biotechnology
    16 May 2012 | 2:51 am
    WFT Cloud, the first certified SAP Cloud Services Partner, continues to provide its customers significant cost savings when migrating or deploying a new Disaster Recovery solution for SAP Production...(PRWeb May 16, 2012)Read the full story at http:...

  • Semba Biosciences Partners with ChromWorks to Accelerate Development…

    Science: Biotechnology
    16 May 2012 | 2:51 am
    Joint effort aims to provide a turnkey solution for enabling accelerated development of novel separation processes for pharmaceuticals, nutraceuticals, functional food ingredients, and renewable...(PRWeb May 16, 2012)Read the full story at http://ww...

  • Norwegian Researchers Discover Novel Marine Based Ingredient for Lower…

    Science: Biotechnology
    16 May 2012 | 2:51 am
    Highly Potent Peptides from Arctic Coldwater Shrimps To Be Commercialized as a Nutraceutical in the Global Markets(PRWeb May 16, 2012)Read the full story at http://www.prweb.com/releases/nofima/marealis/prweb9506809.htm

  • Equine Headshaking: Restoring Normal Blood Pressure is the Key

    Science: Biotechnology
    16 May 2012 | 2:51 am
    With spring in full swing, horses suffering from headshaking will once again challenge their owners when they otherwise should be enjoying the height of the riding season. Managing the symptoms is...(PRWeb May 16, 2012)Read the full story at http://...
 
 
  • add this feed to my.Alltop

    CropBiotech Update

  • FAO Director-General Warns of Horn of Africa, Sahel Funding Gap

    11 May 2012 | 4:00 am
    During the recently concluded international economic forum held in Madrid, Food and Agriculture Organization (FAO) Director-General José Graziano da Silva revealed that funding seems to be the significant problem in the international effort to boost food security and development in Africa. "In the Horn of Africa we are losing the window of opportun...

  • Biotechnology, Key to Realizing Africa's Full Agricultural Potential, says Ghana Minister

    11 May 2012 | 4:00 am
    Agricultural biotechnology has received firm backing from Ghana's Minister for Environment, Science and Technology Hon. Ms. Sherry Ayittey. The Minister's sentiments came during the second Open Forum on Agricultural Biotechnology in Africa (OFAB) all chapters annual planning meeting in Accra, Ghana on May 1, 2012. Hon. Ayittey noted that while Afri...

  • Scripps Research Institute Finds Protein that Can Silence Genes

    11 May 2012 | 4:00 am
    Three-dimensional atomic structure of a human protein which is mainly involved in regulating the activities of cells has been identified by the Scripps Research Institute. This new finding can be helpful in understanding a process called RNA-silencing and use it to treat diseases.The update on RNA-silencing focused on Argonaute2, which is a protein...

  • FAO: Use Your Oil Resources to Improve Agriculture in Africa

    11 May 2012 | 4:00 am
    The FAO Director General José Graziano da Silva has made a clarion call to oil rich African nations to utilize revenues generated from oil to make their countries food secure. Graziano da Silva was speaking during FAO's Regional Conference for Africa on 30 April, 2012 in Brazzaville, Republic of the Congo. "I would like to appeal to African nations...

  • Pollen Allergic Risk Assessment of GM Pepper and GM Chinese Cabbage

    11 May 2012 | 4:00 am
    Scientist Dae-Yul Son of Daegu Haany University and colleagues assessed the allergic risk of pollens coming from genetically modified (GM) pepper with resistance to cucumber mosaic virus and GM Chinese cabbage with high phenylethylisothiocyanate (PEITC) content. They compared the amino acid (AA) sequences of the inserted gene products of GM pepper ...
  • add this feed to my.Alltop

    BioTech News Headlines - Yahoo! News

  • Stem Cell Study Shows Promising Results Against Heart Failure

    10 May 2012 | 10:52 pm
    THURSDAY, May 10 (HealthDay News) -- A new treatment that involves spinning bone marrow stem cells to enhance their healing potential may help people with advanced heart failure feel and function better, a small study suggests.

  • Onetime "King of Biotech" runs afoul of law again

    10 May 2012 | 8:50 am
    NEW YORK (Reuters) - David Blech, an investor who was known as the "King of Biotech" before he admitted to criminal charges of stock manipulation in 1998, has run into trouble with the law again over illegal trades in stocks of two biopharmaceutical companies. Blech told a federal judge in New York on Wednesday that in 2007 and 2008 he bought and sold stocks of Pluristem Therapeutics Inc and Intellect Neurosciences Inc in quick succession to try and conceal his own sales that might have reduced the stock's value. ...

  • Genetic study pins horse domestication to steppes

    7 May 2012 | 3:33 pm
    A genetic study of horses across Eastern Europe and Central Asia has traced the domestication of one of man's most powerful animal allies to wide-open grasslands shared by Ukraine, southwest Russia and Kazakhstan, researchers said Monday.

  • NY medical schools chart progress with stem cells

    7 May 2012 | 9:52 am
    Almost halfway through a $600 million state program supporting stem cell research, eight medical schools around New York are reporting progress on projects such as replicating liver cells and eradicating leukemia cells.

  • Researchers Rejuvenate Blood-Forming Stem Cells in Mice

    3 May 2012 | 11:01 pm
    THURSDAY, May 3 (HealthDay News) -- Researchers who found a way to rejuvenate aged blood-forming cells in mice say their achievement offers clues about how it may be possible to combat health problems associated with old age.
  • add this feed to my.Alltop

    Biology News Net - Biotechnology

  • Researchers use light to switch on gene expression

    10 May 2012 | 4:41 pm
    Imagine being able to control genetic expression by flipping a light switch. Researchers at North Carolina State University are using light-activated molecules to turn gene expression on and off. Their method enables greater precision when studying gene function, and could lead to targeted therapies for diseases like cancer.

  • Research breakthrough for drugs via the skin

    27 Apr 2012 | 3:26 am
    A research team at Karolinska Institutet in Sweden has succeeded in describing the structure and function of the outermost layer of the skin – the stratum corneum – at a molecular level. This opens the way not only for the large-scale delivery of drugs via the skin, but also for a deeper understanding of skin diseases.

  • Prions in the brain eliminated by homing molecules

    24 Apr 2012 | 6:45 pm
    Toxic prions in the brain can be detected with self-illuminating polymers. The originators, at Linköping University in Sweden, has now shown that the same molecules can also render the prions harmless, and potentially cure fatal nerve-destroying illnesses.

  • Compressed sensing allows super-resolution microscopy imaging of live cell structures

    23 Apr 2012 | 6:15 pm
    Researchers from the Georgia Institute of Technology and University of California San Francisco have advanced scientists' ability to view a clear picture of a single cellular structure in motion. By identifying molecules using compressed sensing, this new method provides needed spatial resolution plus a faster temporal resolution than previously possible.

  • Nano-devices that cross blood-brain barrier open door to treatment of cerebral palsy

    23 Apr 2012 | 6:15 pm
    A team of scientists from Johns Hopkins and elsewhere have developed nano-devices that successfully cross the brain-blood barrier and deliver a drug that tames brain-damaging inflammation in rabbits with cerebral palsy.
 
  • add this feed to my.Alltop

    BMC Biotechnology - Latest Articles

  • New cell line development for antibody-producing Chinese hamster ovary cells using split green fluorescent protein

    Yeon-Gu Kim
    14 May 2012 | 7:00 pm
    Background: The establishment of high producer is an important issue in Chinese hamster ovary (CHO) cell culture considering increased heterogeneity by the random integration of a transfected foreign gene and the altered position of the integrated gene. Fluorescence-activated cell sorting (FACS)-based cell line development is an efficient strategy for the selection of CHO cells in high therapeutic protein production. Results: An internal ribosome entry site (IRES) was introduced for using two green fluorescence protein (GFP) fragments as a reporter to both antibody chains, the heavy chain and…

  • Validation of glypican-3-specific scFv isolated from paired display/secretory yeast display library

    Yonghai Li
    6 May 2012 | 7:00 pm
    Background: Glypican-3 (GPC3) is a heparan-sulfate proteoglycan frequently expressed on the cell membrane of malignant hepatocytes in hepatocellular carcinoma. The capacity for screening potential antibodies in vitro using human hepatocellular lines is critical to ensure binding to this highly post-translationally modified glycophosphatidylinositiol-linked protein. We hypothesized that we could utilize a recently described paired display/secretory yeast library to isolate human-derived scFv against glypican-3 for potential diagnostic and/or therapeutic application. Methods: Using two…

  • Untranslated regions of diverse plant viral RNAs vary greatly in translation enhancement efficiency

    Qiuling Fan
    5 May 2012 | 7:00 pm
    Background: Whole plants or plant cell cultures can serve as low cost bioreactors to produce massive amounts of a specific protein for pharmacological or industrial use. To maximize protein expression, translation of mRNA must be optimized. Many plant viral RNAs harbor extremely efficient translation enhancers. However, few of these different translation elements have been compared side-by-side. Thus, it is unclear which are the most efficient translation enhancers. Here, we compare the effects of untranslated regions (UTRs) containing translation elements from six plant viruses on…

  • RNA viral vectors for improved Agrobacterium-mediated transient expression of heterologous proteins in Nicotiana benthamiana cell suspensions and hairy roots

    Jeffrey Larsen
    5 May 2012 | 7:00 pm
    Background: Plant cell suspensions and hairy root cultures represent scalable protein expression platforms. Low protein product titers have thus far limited the application of transient protein expression in these hosts. The objective of this work was to overcome this limitation by harnessing A. tumefaciens to deliver replicating and non-replicating RNA viral vectors in plant tissue co-cultures. Results: Replicating vectors derived from Potato virus X (PVX) and Tobacco rattle virus (TRV) were modified to contain the reporter gene beta-glucuronidase (GUS) with a plant intron to prevent…

  • Isolation and characterization of wharton's jellyderived multipotent mesenchymal stromal cells obtained from bovine umbilical cord and maintained in a defined serum-free three-dimensional system

    Tereza Cardoso
    3 May 2012 | 7:00 pm
    Background: The possibility for isolating bovine mesenchymal multipotent cells (MSCs) from fetal adnexais an interesting prospect because of the potential for these cells to be used forbiotechnological applications. Bone marrow and adipose tissue are the most common sourcesof MSCs derived from adult animals. However, little knowledge exists about thecharacteristics of these progenitors cells in the bovine species. Traditionally most cellcultures are developed in two dimensional (2D) environments. In mammalian tissue, cellsconnect not only to each other, but also support structures called the…
  • add this feed to my.Alltop

    Biotechnology Journal

  • Comparative reaction engineering studies for succinic acid production from sucrose by metabolically engineered Escherichia coli in fed-batch operated stirred tank bioreactors

    Torben Hoefel, Georg Faust, Liv Reinecke, Nicolas Rudinger, Dirk Weuster-Botz
    16 May 2012 | 4:50 am
    AbstractThis study presents a comparative reaction engineering analysis of metabolically engineered sucrose utilizing Escherichia coli derived from E. coli K12 MG1655 for the anaerobic production of succinic acid. Production capacities of 16 different recombinant strains were evaluated in 48 parallel fed-batch operated milliliter-scale stirred tank bioreactors (V = 10 mL) with continuous CO2-sparging. The effects of recombinant sucrose utilization systems (csc-operon or scr-operon), enhancements of anaplerotic reactions (pck, ppc, maeA, maeB or heterologous pyc) and gene deletions (ldhA,…

  • Mediators of induced pluripotency and their role in cancer cells – current scientific knowledge and future perspectives

    Mathias Bernhardt, Marta Galach, Daniel Novak, Jochen Utikal
    16 May 2012 | 4:50 am
    AbstractThe discovery that overexpression of the transcription factors Oct4, Sox2, Klf4 and c-Myc reprograms differentiated cells into “induced pluripotent stem cells” (iPSCs) has extended our understanding of mechanisms required to maintain stem cell pluripotency and to drive differentiation. Subsequently, additional factors have been discovered that are able to induce a pluripotent state. Recently several groups have succeeded in reprogramming cancer cells to iPSC-like induced pluripotent cancer cells by use of the method established for the generation of iPSCs. This discovery…

  • Identification of leukemia stem cells in acute myeloid leukemia and their clinical relevance

    Van Thanh Hoang, Abraham Zepeda-Moreno, Anthony D. Ho
    16 May 2012 | 4:50 am
    AbstractAcute myeloid leukemia (AML) is considered to be a disease of stem cells. A rare defective stem cell population is purported to drive tumor growth. Similarly to their normal counterparts, leukemic stem cells (LSC) divide extreme slowly. This may explain the ineffectiveness of conventional chemotherapy in combatting this disease. Novel treatment strategies aimed at disrupting the binding of LSC to stem cell niches within the bone marrow might render the LSC vulnerable to chemotherapy and thus improving treatment outcome. This review focuses on the detection of LSC, our current…

  • Programmable genetic switches to control transcriptional machinery of pluripotency

    Ganesh N. Pandian, Hiroshi Sugiyama
    16 May 2012 | 4:50 am
    AbstractTranscriptional activators play a central role in the regulation of gene expression and have the ability to manipulate the specification of cell fate. Pluripotency is a transient state where a cell has the potential to develop into more than one type of mature cell. The induction of pluripotency in differentiated cells requires extensive chromatin reorganization regulated by core transcriptional machinery. Several small molecules have been shown to enhance the efficiency of somatic cell reprogramming into pluripotent stem cells. However, entirely chemical-based reprogramming remains…

  • Using the Cre/lox system for targeted integration into the human genome: loxFAS-loxP pairing and delayed introduction of Cre DNA improve gene swapping efficiency

    Amanda M. Lanza, Timothy J. Dyess, Hal S. Alper
    16 May 2012 | 4:48 am
    AbstractCre recombinase is a commonly-used genome editing tool suitable for site-specific integrations in mammalian genomes; however, the efficiency of transgenic swapping events compared to excision remains limited. Here we sought to identify important parameters and limiting factors that influence swapping propensity in this system, especially when using one wild-type loxP site. To modulate and increase the occurrence of swapping events, we identified two novel parameters. First, we identified the loxFAS-loxP pairing, a sequence never before used in mammalian systems, as the best choice for…
  • add this feed to my.Alltop

    biotechnology « WordPress.com Tag Feed

  • New Orleans InfoWars video entry: Chemtrails, GMOs & Transgenics

    Rady
    2 May 2012 | 12:36 pm
    By Rady Ananda Activist Post In this 10-minute entry into Alex Jones’ wildly popular video news cont

  • A Living Hearth

    sevenfoldhealing
    2 May 2012 | 12:29 pm
    Old Irish Hearth Lough Doolin C. Clare (Photo credit: Wikipedia) The word hearth is often used with the word home. The hearth is the home’s centerpiece, the focal point of its society, the source of its comfort and nourishment. The hearth is so iconic that even Michael Reynolds, son of a Baptist minister and designer of the Earthship, built one into his home for use once a year, on Christmas. Like wildfires that consume forests, domestic fires consume dead matter to release flames, smoke, and heat. They turn wood into ashen lye, oil into acid rain, and a slow process of rot into a brief,…

  • Science, Technology, and Vivid Property

    nabans
    2 May 2012 | 11:50 am
    Science and technology provide many societal benefits, such as the enhancement of economic growth or quality of life. They also can produce negative, unintended consequences. Most societies promote science and technology, but this can be costly. Establishment of IPRs that protect new works and give innovators the right to profit from their creations provides incentives for expensive innovation without the need for direct government subsidies. At the same time, IPRs may maintain or aggravate wealth inequities. Rights have little meaning unless they can be enforced and modern technology has…

  • Keystone Innovation Zones

    malvernconsultinggroup
    2 May 2012 | 7:22 am
    State-designated districts called Keystone Innovation Zones are at the heart of efforts to make Pennsylvania and Philadelphia havens for companies that employ well-educated people in high-paying jobs. It is a state effort to attract so-called knowledge workers to focus on stimulating the development of the biotechnology industry and encouraging venture capital firms to invest in Pennsylvania companies. The zones are created for entrepreneurial companies to grow therefore furthering the focus on boosting the amount of money available to startups and making the area a hub for nanotechnology…

  • Global market for commercial biotechnology separation systems to grow to $26.7 billion by 2016

    vikas@bccr
    2 May 2012 | 7:19 am
    The global market for commercial biotechnology separation systems was about $12.1 billion in 2010 an
 
  • add this feed to my.Alltop

    Colorado BioScience Association News Feed

  • CBSA Applauds Dr. Larry Gold & Team for Organizing Gold Labs Symposium 2012

    14 May 2012 | 5:59 pm
    Colorado BioScience Association (CBSA) applauds organizers of the third annual Gold Lab Symposium that will take place on the University of Colorado campus with over 400 attendees, on Friday and Saturday, May 18 - 19, 2012. The two-day event titled “Time: Tempus Fugit” brings 16 renown national and international scientists and healthcare experts together to discuss progress and issues in personalized medicine. The announcement is made by Holli Riebel, CBSA President & CEO, who says, “We are honored to assist the Gold Lab Symposium—the speakers are incredible visionaries from an…

  • Aurora Sentinel: 'Venture contest a capital idea for local bioscience start-ups looking for cash'

    3 May 2012 | 12:16 pm
    Quoting from the May 1st article by Brandon Johansson: "It’s no secret that finding investors is one of the biggest challenges bioscience start-up companies face. But a contest this fall is aiming to help some local start-ups land a little extra money and advice on how to make their business more enticing to investors. The Colorado BioScience Association announced last week it is accepting nominations from emerging bioscience companies for the Venture Showcase Competition at BioWest 2012 conference this September. The deadline for nominations is May 11." Special note: the 2012 Venture…

  • CBSA Event Coverage: 'Tax on medical devices threatens profits, exec says'

    3 May 2012 | 11:11 am
    Quoting from the April 27th article by Wayne Heilman: "A tax on medical devices approved in 2010 as part of federal health care reform legislation would wipe out all of the profits Colorado Springs-based Spectranetics Corp. expects to make this year when the tax takes effect next year, a top company executive said... ...'We aren’t going to cut back on product development or clinical research, but as we think about investing in the future we will probably think twice and be able to do less of it,' Childs [Guy Childs, chief financial officer of Spectranetics] told about 120 business and civic…

  • Colorado BioScience Association Seeks Region’s Top Start-up Companies for Venture Showcase Competition at BioWest 2012

    24 Apr 2012 | 8:35 am
    Colorado BioScience Association (CBSA) is now accepting applications from emerging bioscience companies for the Venture Showcase Competition at BioWest 2012, being held September 11th at the Marriott City Center, Denver. The announcement is made by CBSA President & CEO Holli Riebel, who says, "Six finalists will be selected from the applicants and the winner will receive a $7,500 cash prize at the competition." "The Venture Showcase creates a huge amount of excitement at the BioWest Conference and gives our emerging bioscience companies an opportunity to present their technologies on a…

  • NCBR: 'Ventria looks for breakthrough plant-based drugs'

    21 Apr 2012 | 12:43 pm
    Quoting from the April 20th NCBR article by Steve Lynn:"Ventria Bioscience is making a drug that CEO Scott Deeter hopes somedaywill generate several billion dollars in revenue. There are, of course, a few hurdles first. Ventria has developed a method to make proteins and store them in self-pollinating plants such as rice and barley. The company plans to use those proteins, developed affordably and on a large scale, in drugs for worldwide distribution... ...'They’re special because the material they use is plant-based, which is different from other companies that provide proteins for…
  • add this feed to my.Alltop

    OnBioVC

  • SEA Medical Systems, Inc.: Series B $3M

    arubenstein
    24 Apr 2012 | 2:00 am
    SEA Medical Systems (Santa Clara, CA) a development-stage medical device company focused on IV drug, concentration and diluent monitoring devices for safety and prevention of drug errors, closed a $3M Series B financing. Participants include JK&B Capital.

  • AirXpanders, Inc.: Series D $10.3M

    arubenstein
    24 Apr 2012 | 2:00 am
    AirXpanders (Palo Alto, CA) a clinical-stage biotechnology company focused on implantable breast tissue expanders for breast cancer masectomy patients, closed a $10M Series D financing. Participants include Vivo Ventures, GBS Venture Partners, Prolog Ventures, Heron Capital and Western Technology Innovation.

  • MC10, Inc.: Series B $2M

    arubenstein
    24 Apr 2012 | 2:00 am
    MC10 (Cambridge, MA) a development-stage medical device company focused on flexible, portable electronic medical devices for diagnosing, monitoring body functions and performance via parameters such as the heart (ECG), brain (EEG), muscle (EMG), body temp and hydration, closed a $2M Series B financing, bringing the total round to $17.1M. Participants include Aberdare Ventures.

  • CN Creative, Ltd.: Series A $3.1M

    arubenstein
    24 Apr 2012 | 2:00 am
    CN Creative (United Kingdom) a development-stage medical device company focused on electronic nicotine delivery devices and other nicotine replacement therapies for nicotine addiction and smoking cessation, closed a $1M Series A financing. Participants include Advent Life Sciences.

  • ImmuneXcite, Inc.: Series A $2.4M

    arubenstein
    24 Apr 2012 | 2:00 am
    ImmuneXcite (Watertown, MA) a development-stage biopharmaceutical company focused on a therapeutic platform for the development of monoclonal antibodies and vaccines for cancer and infectious diseases, closed a $2.4M Series A financing. Participants include Boston Harbor Angels.
  • add this feed to my.Alltop

    BioSpace.com Featured News and Stories

  • A Little More Education, a Little Longer Life? Study

    15 May 2012 | 7:00 am
    It's graduation season, and new research offers yet another reason to congratulate someone who has completed at least nine years of education: They're likely to live longer. An unusual, comprehensive study involving 1.2 million Swedes shows that students who were exposed to nine years of education rather than eight had a lower mortality rate after age 40. While the finding suggests an association between...

  • AstraZeneca PLC Slashes 400 More Jobs in Sweden

    15 May 2012 | 7:00 am
    Another 400 jobs will be cut from Anglo-Swedish pharmaceutical manufacturer Astra Zeneca, the company has announced, with the majority of the redundancies in Sdertlje, south of Stockholm. According to the company this is an implementation of the cuts that the company presented in February, when the company announced that 1,100 employees would have to go. We realized already then that it was administrative...

  • Promedior Moves Fibrosis Pipeline to Boston, Hires Shire plc Vet as CEO

    15 May 2012 | 7:00 am
    MALVERN, Penn., May 15, 2012 (BUSINESS WIRE) -- --Company to Relocate Headquarters to Boston Area Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, today announced the appointment of Suzanne L. Bruhn, Ph.D., as President and Chief Executive Officer. Dr. Bruhn takes on the role of CEO at a time when Promedior is rapidly advancing...

  • Gene Therapy Dramatically Extends Mouse Lifespan, Study

    15 May 2012 | 7:00 am
    A new study consisting of inducing cells to express telomerase, the enzyme which -- metaphorically -- slows down the biological clock -- was successful. The research provides a "proof-of-principle" that this "feasible and safe" approach can effectively "improve health span."

  • Achillion Pharmaceuticals, Inc.'s Hepatitis C Drug Gets FDA Fast Track

    15 May 2012 | 7:00 am
    NEW HAVEN, Conn., May 15, 2012 (GlobeNewswire via COMTEX) -- Achillion Pharmaceuticals, Inc. /quotes/zigman/100395/quotes/nls/achn ACHN 2.32% announced today the receipt of a Fast Track designation from the U.S. Food and Drug Administration (FDA) for ACH-3102 as part of an interferon-free regimen for the treatment of chronic hepatitis C (HCV). ACH-3102 is a pan-genotypic second-generation NS5A inhibitor...
 
  • add this feed to my.Alltop

    Bioresearch Online News

  • Groundbreaking Alzheimer's Disease Prevention Trial Announced

    15 May 2012 | 11:49 pm
    In collaboration with the National Institutes of Health (NIH), Banner Alzheimer’s Institute (BAI), University of Antioquia in Colombia and Genentech, a member of the Roche Group (SIX: RO,ROG;OTCQX:RHHBY), announce the first-ever prevention trial in cognitively healthy individuals who are destined to develop Alzheimer’s disease because of their genetic history.

  • Corporate Espionage Is Real — Even In The Pharma Industry

    15 May 2012 | 8:05 pm
    Imagine you spent the past 15 years of your life passionate about finding a cure for Alzheimer’s.You stayed up nights struggling to continue your research, yet you were running out of funding.Knowing your competitors were years behind your research, you finally found your angel investorwho provided the seed capital you needed — but with the time-sensitive precondition that youmust provide a return on investment within two years or they would pull your financing.By Jonathan Snyder

  • Connecting The FDA And Pharma / Biotech Industry

    15 May 2012 | 7:57 pm
    Even with more than 8,800 employees and an annual budget of around $3.2 billion, the FDA’stask of protecting the public health seems daunting, considering the complexity of products beingdeveloped by industry.By Rob Wright

  • Biomanufacturers Increasing Budgets For Upstream & Downstream Production

    15 May 2012 | 7:48 pm
    Nearly 65% of biomanufacturers are planning to increase their budgets for newtechnologies to improve efficiencies and costs for downstream production, and three outof every five are increasing funding for new upstream production technologies.By Eric Langer, president and managing partner, BioPlan Associates, Inc.

  • CROs & CMOs: Focusing On Innovation

    15 May 2012 | 7:41 pm
    In 2011, innovation was a major topic among the various players in the drugdevelopment industry. Feedback from clients and sponsor-side industry personnelprompted a change in the outsourcing drivers included in the Nice InsightPharmaceutical and Biotechnology Outsourcing survey, such that innovation — or theability to improve in-house capabilities with customized solutions — replacedaccessibility for the 2012 research cycle.By Kate Hammeke, research manager, Nice Insight
  • add this feed to my.Alltop

    Life-Sciences

  • Discounted on Amazon already

    David Bradley
    21 Apr 2012 | 5:15 am
    My new book, which I just mentioned not 5 minutes ago, and for which I’ve not actually signed the physical, paper contract nor done much more than the basic table of contents and a single “typeset test” chapter, is already on Amazon and discounted from the list price by 10%. Maybe it’ll be available for a quid by the time I’ve actually written it: I assume you could pre-order here: Deceived Wisdom The illustration shows an early mock-up of the cover, it will most likely change…or not, as the case may be. The latest version of the cover should appear on the…

  • Explosive Alchemist

    David Bradley
    8 Apr 2012 | 3:49 am
    An explosive start to this weeks Alchemist, well actually its a non-explosive start thanks to a reaction scheme that tames diazomethan. In the world of X-ray crystallography, we learn that the bound structure of a drug to treat hepatitis C has been determined and in materials science, truly alchemical-sounding chemistry reveals that Beaujolais is the tipple of choice when preparing iron telluride superconductors. A new approach to pump-probe techniques is more robust and stable than before and the alchemist learns that residues from radiotherapy could allow environmental scientists to trace…

  • 2012 Biotech Humanitarian Award Nominations Open

    yfriedman
    3 Apr 2012 | 2:51 pm
    I am once again honored to be judging the Biotech Humanitarian Award. The Biotech Humanitarian Award is given to an individual who has harnessed the potential of biotechnology to heal, fuel or feed the planet. Last year’s Honoree was Dr. Paul Offit, a vaccine advocate who serves as the Chief of the Division of Infectious Diseases and the Director of the Vaccine Education Center at The Children’s Hospital of Philadelphia. Dr. Offit was presented the Humanitarian Award in recognition of his 25 years spent dedicated to developing RotaTeq, one of the main vaccines currently used to fight…

  • Liver disease kills

    David Bradley
    22 Mar 2012 | 9:11 am
    Given my slightly worrying feedback from the Fenland Study, my neurotic brain latched on to the headlines today in which male 40-somethings seem to be dropping like flies, jaundiced and with failed livers. The BBC reports: “Deaths from liver disease in England have reached record levels, rising by 25% in less than a decade, according to new NHS figures. The reports say that heavy drinking, obesity and hepatitis are to blame, with 37% of deaths due to alcohol abuse. Obesity is apparently on the rise, but why are liver problems due to hepatitis on the rise too? Now, cutting back on fats,…

  • BioJobBlog Domain Name Held Hostage By GoDaddy.com

    cmintz
    10 Mar 2012 | 2:07 pm
    Some of you may be wondering what happened to my blog posts on blog notions.  I apologize for not providing new content but due to an internal error committed by service representatives at GoDaddy.com the domain name biojobblog.com that I owned for 7 years was purchased by a new registrant (who I believe contacted me a few days before the domain was to expire–unbeknowst to me) and asked me to quote a price for it. Suffice it to say, I had no idea why out of the blue somebody would want to purchase my domain name. Unfortunately, due to Go.Daddy’s internal error (they fused two…
  • add this feed to my.Alltop

    Genome Engineering

  • Gene therapy for hearing loss

    Suzanne Elvidge
    14 May 2012 | 5:24 am
    Hearing loss can be caused by advancing years, or by head injuries or loud noises, all of which lead to loss of the sensory hair cells. A new gene therapy could have potential to replace the damaged hair cells, but isn't likely to be the answer by itself. The study was published in the Journal of Neuroscience.

  • Hints & tips: FusionAnalyser – a graphical tool for fusion rearrangements discovery

    Suzanne Elvidge
    13 May 2012 | 10:29 am
    Hints & tips from Nucleic Acids Research: FusionAnalyser - a new graphical, event-driven tool for fusion rearrangements discovery.

  • Hints & tips: Top 8 reasons for high background noise on your western blot

    Suzanne Elvidge
    13 May 2012 | 10:02 am
    Hints & tips from American Biotechnologist: Top 8 reasons for high background noise on your western blot.

  • The Genome Engineering Game for May – Cut It Out

    Suzanne Elvidge
    10 May 2012 | 11:00 pm
    It's Friday, so have a break and play the Genome Engineering game for May – Cut It Out.

  • Genes and body clocks

    Suzanne Elvidge
    6 May 2012 | 11:00 pm
    The 'body clock' or circadian rhythms controls things like alertness, sleep patterns, appetite and hormones, and travelling across time zones or working nights can disturb it. Researchers from the University of Sydney and from the Salk Institute have worked on how the genes behind this are controlled and their research was published in Nature.
 
  • add this feed to my.Alltop

    News

  • Scientist uses stem cells to rebuild bone

    mhollmer
    14 May 2012 | 4:16 pm
    In the move to use induced pluripotent stem cells to both repair and replace damaged bone tissue in patients, recent research by scientist Darja Marolt has helped advance the field in a major way. The investigator with The New York Stem Cell Foundation laboratory has used human embryonic stem cells to successfully grow bone tissue grafts, according to the foundation. And they're not just a half-hearted first attempt: In mice, the foundation claims, Marolt and her team have proven in a recent study that the new bone growth is strong enough to support major bone tissue regeneration,…

  • Compounds may combat cancers by reversing p53 mutation

    mhollmer
    14 May 2012 | 2:16 pm
    Let's talk about the p53 protein for a minute. The Star-Ledger describes it as "a kind of intracellular security force" that smacks down cells when they start veering from their designated path. Confronted by cancer, however, p53 mutates and becomes impotent, leading to tumors and the spread of more than 60% of all cancers. But now scientists at the Cancer Institute of New Jersey and the Institute for Advanced Study have identified a class of compounds--known as thiosemicarbazones--that appears in early testing to correct p53's mutation in mice. Treated with the…

  • How do you make a deaf mouse hear? Emory University tries gene therapy

    mhollmer
    11 May 2012 | 4:08 pm
    How can you help deaf mice regain their ability to hear? It sounds like the first half of a joke, but it's not. Researchers at the Emory University School of Medicine are part of the way toward figuring out a method that could eventually work, using gene therapy that helped promote the growth of new sensory hair cells in the inner ear. But the treatment seemed to benefit pre-pubescent mice far more than adult ones. Read about the details in the Journal of Neuroscience. But the gist of what they accomplished is this: Bringing the Atoh1 gene into the cochleae of young mice helped promote…

  • Preclinical breakthrough: Scientists beat rare skin cancer tumors

    mhollmer
    10 May 2012 | 4:52 pm
    Merkel cell carcinoma isn't the most common form of cancer. As the National Cancer Institute notes, only 1 person in 227,000 develops it in the United States each year. But the cancer affects older adults, people with weakened immune systems, and patients who are in the sun too much, and it can be very deadly, growing quickly and metastasizing early. That's what makes a new finding by a husband and wife team of scientists (Patrick Moore and Yuan Chang) at the University of Pittsburgh all the more noteworthy. As Essential Public Radio reports in a story posted online, the pair tested…

  • Researchers cure Type 1 diabetes in mice

    mhollmer
    10 May 2012 | 4:22 pm
    A dose of antibodies, a bone marrow transplant and treatment with pancreas growth factor helped cure late-stage Type 1 diabetes in mice, researchers have found. The effort, led by City of Hope National Medical Center endocrinologist Defu Zeng, is detailed in the journal Science Translational Medicine. Bloomberg also reports on the findings with a solid story rounding up some of the crucial fine points. As always, take these findings with a grain of salt. Results in mice and other animal trials can be enticingly encouraging, with researchers subsequently finding that they can't repeat the…
  • add this feed to my.Alltop

    News

  • UPDATED: Mobile apps could rival pharma's crown jewels

    rmcbride
    15 May 2012 | 7:53 am
    As we pack more data about our health into mobile devices, pharma companies could face a new competitive threat to their drugs: Mobile health apps. Forbes contributor Dave Chase notes that anecdotal evidence indicates that mobile apps could provide greater benefits for some patients with certain diseases than some drugs, which could lead doctors to prescribe the digital remedies to their patients once the apps showed greater benefits than traditional meds. The threat looms closer than one might think. Happtique, a mobile health outfit, has launched a trial to test the use of its pioneering…

  • NIH pumps $6M into DNA analysis for Alzheimer's plan

    rmcbride
    14 May 2012 | 9:29 am
    President Barack Obama has waged war on Alzheimer's disease and pushed federal agencies to boost their awards for studies of the memory-stealing disease--and understanding the ememy at the genomic level is a key to victory. As GenomeWeb reports, the National Institutes of Health's National Institute on Aging has heeded the president's call for action and awarded up to $6 million for three projects that aim to analyze DNA sequencing data related to Alzheimer's. The institute says the awards are part of the president's initiative. Article

  • UPDATED: BioClinica chief touts Microsoft ties in Q1 report

    rmcbride
    14 May 2012 | 9:08 am
    BioClinica ($BIOC) capitalized on the compatibility of its clinical trials software with Microsoft ($MSFT) technology and boosted revenue and income during the first quarter that ended March 31, the company said last week. And the provider of clinical trials software and medical image management continued to build on record business backlogs. Newtown, PA-based BioClinica grew service revenue 14.9% from $16.1 million to $18.6 million, according to the company, which reiterated its guidance for full-year service revenue of $73 million to $77 million. The company's backlog jumped…

  • Boehringer, pharmas turn to social gaming for online outreach

    rmcbride
    14 May 2012 | 8:27 am
    Call it PharmaVille. As drugmakers seek creative ways to dazzle consumers online, they have ripped pages from the playbooks of gaming companies that have made digital pastimes such as "FarmVille" popular on Facebook. And so-called "gamification" has generated plenty of buzz among drug company marketers, InPharm reports. Take Boehringer Ingelheim, which made public months ago that the German drugmaker wants to create a social game dubbed "Syrum" that would let players tend to virtual R&D projects and traffic in scientific talent and compounds,…

  • Roche unit allies with genomics software group SoftGenetics

    rmcbride
    14 May 2012 | 7:34 am
    Roche's 454 Life Sciences has struck a partnership with SoftGenetics, a provider of next-generation sequencing (NGS) analytics. The co-op calls for Roche/454 and SoftGenetics to join forces in production promotions, the software company says. With biologists struggling to make use of a rising tide of NGS data, SoftGenetics provides analysis software in tune with 454 sequencing data, according to the company. SoftGenetics' technology applies to multiple types of sequencing jobs, including amplicon resequencing, exome sequencing and forensic profiling. The deal follows a string of…
  • add this feed to my.Alltop

    Eye Tracking Update

  • The race for augmented reality glasses

    mfox
    15 May 2012 | 2:30 pm
    Microcameras, wearable displays, and eye tracking…that sounds like a hot topic right up our alley! The latest buzz is all about augmentative reality glasses. The race is on and the competition is fierce as tech companies ranging from small start ups to giants like Google, are working hard to launch this futuristic technology on the [...]Check Out The Free Eye Tracking Industry ReportRelated articles:The Congruence of Eye Tracking and Augmented RealityEye Tracking and Augmented Reality: The Future of AdvertisingEye Tracking and Augmented Reality: An Interview With Metaio CEO

  • Expert Vs Novice: Eye tracking applications in law enforcement

    mfox
    4 May 2012 | 3:52 pm
    You’ve most likely seen an old Western-style shootout where the good cowboy and the bad cowboy pace out in opposite directions then simultaneously turn and draw. Of course, in the movies, the good cowboy was usually the quickest to draw, and therefore the one to walk away alive. However, a study by the Force Science [...]Check Out The Free Eye Tracking Industry ReportNo related posts.

  • Eye tracking: the future of in-flight entertainment

    mfox
    18 Apr 2012 | 3:16 pm
    What would make your long distance flight more enjoyable than an in-air eye tracking experience? Maybe a few extra inches of leg room, but the concept envisioned by Panasonic for the future of in-flight entertainment (IFE) sounds pretty sweet. Panasonic is seeking to “enlarge passengers’ onboard environment” in terms of both physical and perceived space. [...]Check Out The Free Eye Tracking Industry ReportNo related posts.

  • Eye tracking’s future role in data analytics

    mfox
    28 Mar 2012 | 5:30 pm
    The fastest growing market for eye tracking is in market research and usability. The value of knowing not only where customers are looking but how they are looking is becoming more widely recognized. There is a vast amount of data that can potentially be collected about online user behavior using eye tracking. For example, did [...]Check Out The Free Eye Tracking Industry ReportNo related posts.

  • The eye tracking price-quality tradeoff

    mfox
    21 Mar 2012 | 5:26 pm
    After reviewing our Eye Tracking Update stats for the last six months, it appears that there is significant interest in articles related to the price of eye tracking. This doesn’t really come as a surprise, as the cost of eye tracking is notoriously high and there are many inventors who are seeking to develop low [...]Check Out The Free Eye Tracking Industry ReportRelated articles:Eye Tracking Cost: a Tradeoff for Quality?The Price of Eye Tracking
 
  • add this feed to my.Alltop

    Reportergene

  • WTF is in a kit? [ipse dixit #3]

    Gianpaolo R
    10 May 2012 | 11:35 am
    or: Why I'm dismissing molecular biology kits Qiagen workers making the secret recipe - Jeffrey/MacMillan for: Capital Business I love kits as a concept. They are practical and save time. Making and storing buffers takes time (and space), I prefer having more time to read and think. Because I prefer making better science than spending my day around a plasmid miniprep, or maybe because I'm a little lazy. Despite I love assay kits in theory, I'm dismissing some of them, because I don't know what is inside the bottle, so I don't know how to play my Goldberg variations. The point is very well…

  • New Brainbow Hearth: lineage analysis

    Gianpaolo R
    7 May 2012 | 6:43 am
    The creative use of reporter genes uncover a new mechanism shaping vertebrate organ development During development, the heart must accomodate to pump all the blood required by the incresing size of the organism. In fact, the heart can enhance its functional capacity by expanding its volume and increasing its muscle mass. How does this translate at cellular levels? Is that each heart cell proliferates steadily and contributes equally, or maybe small subpopulations have more labour? This is a classical question that can be answered by lineage analysis: the fate mapping of single cells over…

  • Cover - new paper about a mitosis-reporter mouse model

    Gianpaolo R
    13 Apr 2012 | 8:13 am
    Molecular imaging of NF-Y transcriptional activity maps proliferation sites in live animals. Mol Biol Cell., 2012 23(8); 1467-74 doi:10.1091/mbc.E12-01-0039 Goeman F, Manni I, Artuso S, Ramachandran B, Toietta G, Bossi G, Rando G, Cencioni C, Germoni S, Straino S, Capogrossi MC, Bacchetti S, Maggi A, Sacchi A, Ciana P, Piaggio G. Abstract In vivo imaging involving the use of genetically engineered animals is an innovative powerful tool for the noninvasive assessment of the molecular and cellular events that are often targets of therapy. Based on the knowledge that the activity of the Nuclear…

  • [Cool site] Biology.SE - the first 100 days

    Gianpaolo R
    22 Mar 2012 | 8:40 am
    My preferred online place to exchange biology knowledge. This is the most interesting Q&A site for biology researchers, academics, and students I stumbled upon so far. I'm really excited about it and since some increased participation is required to exit the beta stage, I'm inviting you to have a visit and consider joining. Forget noncurated forums plenty of 'why my beta galactosidase assay does not work?' kind of questions. This is not a forum. The day after tomorrow, Biology.StackExchange.com will cross its first 100 days of life, accumulating some 500 relevant questions and…

  • Selling your ideas like Gyro Gearloose

    Gianpaolo R
    6 Mar 2012 | 1:30 pm
    We saw that crowdsourcing pays some cheques to the scientist making his own research lab in the garage. But how to find a relevant research demand? You have already read about Fold.it, the site where people play online to solve protein structure for free. Imagine now an online pavillion who is actually paying the intellectual work of scientists working at home through different calls - named Challenges - to take part in a real scientific problem. This is InnoCentive. There are different challenge calls on InnoCentive: the theoretical one, the analytical one, etc. Take a look on their…
  • add this feed to my.Alltop

    B3C newswire

  • Vetter Boosts Quality and Logistic Processes

    11 May 2012 | 9:00 am
    Leading CDMO completes its brand new Center for Visual Inspection and Logistics Ravensburg, Germany, May 11, 2012 / B3C newswire / – The pharma and biotech industries are increasingly seeking safer and more efficient supply chain processes. To meet these challenges Vetter has invested in a new, state-of-the-art Center for Visual Inspection and Logistics. The new facility offers high-bay warehousing capacity for cool and room-temperature goods employing state-of-the-art technology. The contract development and manufacturing organization (CDMO) is also setting high safety standards…

  • Definiens Expands Functionality of Its Leading Solution for Quantitative Digital Pathology with ...

    10 May 2012 | 10:00 am
    Definiens Tissue Studio Now Supports the Detection of Spot-like Signals from In Situ Hybridization Assays Munich, Germany, May 10, 2012 / B3C newswire / - Definiens®, the leading provider of image analysis and data mining solutions for quantitative digital pathology, today announced that Definiens Tissue Studio® 3.5 now supports the automated analysis of in situ hybridization assays, including SISH, CISH, FISH and dual-ISH. The unique combination of flexibility and ease-of-use that characterizes Definiens Tissue Studio® significantly facilitates the detection of spot-like…

  • Antisense Pharma Internationalizes Management Board

    10 May 2012 | 6:15 am
    Dr. Philippe Calais appointed Chief Executive Officer (CEO) Regensburg, Germany, May 10, 2012 / B3C newswire / - The biopharmaceutical company Antisense Pharma announces the appointment of Dr. Philippe Calais as CEO. The native-born Frenchman has more than two decades of international experience in executive positions in biotech and pharmaceutical companies – including Hofmann La-Roche and ICI Pharmaceuticals – and has successfully guided several medicines from their clinical development to their commercialization. Dr. Calais steps in for interim Chief Executive Officer…

  • Mucosis Announces Positive Proof-Of-Concept Data for Mimopath® Platform In Humans

    10 May 2012 | 1:00 am
      Groningen, the Netherlands, May 10, 2012 / B3C newswire / - Dutch vaccine development company Mucosis B.V. today announced Phase I clinical data providing proof-of-concept that Mimopath®-based mucosal vaccines are safe and well tolerated as well as able to produce balanced immune responses in both circulating blood and the respiratory tract. Mucosis, in conjunction with the Centre for Human Drug Research (CHDR; Leiden, the Netherlands), conducted the clinical trial to assess the safety, tolerability, and immunogenicity of nasally administered FluGEM®, a Mimopath®-based…

  • Nuevolution Announces Receipt of Milestone Payment from Boehringer Ingelheim

    9 May 2012 | 7:00 am
    Copenhagen, Denmark, May 9, 2012 / B3C newswire / – Nuevolution A/S today announced that it has received a milestone payment derived from its collaboration with Boehringer Ingelheim.  The payment was triggered following identification of potent small molecule compounds that have been shown to disrupt the protein-protein interaction of an undisclosed therapeutic target.  In its collaboration with Boehringer Ingelheim, Nuevolution is applying its proprietary Chemetics® technology to identify novel small molecule leads against drug targets of interest to Boehringer…
Log in